新抗てんかん剤Sodium Dipropylacetate （DPA）の使用経験

Clinical Evaluation of Dipropylacetate (DPA), a New Anti-Epileptic Drug

I．はじめに

　Sodium Dipropylacetate （以下DPAと省略）は，フランスのBerthier Laboratoriesで開発された新抗てんかん剤である。本剤の化学構造式は第1図のごとくで，小発作・精神運動発作についで大発作や，大発作・小発作の混合型にも単独に，あるいは他の抗てんかん剤と併用しての効果が確認されている^1）2）。

　今回われわれは，各種てんかん患者に本剤を試用する機会を得たので，その結果について報告する。

An attempt was made to evaluate the clinical effect of DPA in the treatment of various types of 48 epileptics and of the periodic myoclonic jerks of extremities of a patient with subacute sclerosing leucoencephalitis (S. S. L. E.). The efficacy of this drug was noted in 24 (60%) of 40 epileptics who had been subjects to clinical evaluation in this study. The drug was effective to grand mal and focal seizures. It was also effective in 2 of 3 patients with petit mal absence and to the periodic myoclonic jerks of S. S. L. E.

Side effects were noted in 12 patients (25%), though they were minor ones, except one patient who developed fever and exanthema with this drug.

It is concluded that DPA is valuable drug, espe-cially when it is used in combination with other anti-epileptics in the treatment of epileptics.